ALXN2040

today NCT05708573 · Ph 1

2023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT05708573	Feb → Mar 2023	—	Alexion Pharmaceuticals, Inc.	Completed	No outcome recorded

Date	Issuer	Release
2022-09-16	AstraZeneca	Danicopan (ALXN2040) add-on to Ultomiris or Soliris met primary endpoint in ALPHA Phase III trial for patients with paroxysmal nocturnal haemoglobinuria who experience clinically significant extravascular haemolysis astrazeneca.com ↗

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	ALXN2040	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05708573 ↗
Route	Oral	“oral tablets of ALXN2040” NCT05708573 ↗